Markets
BSE See NSE See 39,343.47
230.73 (0.59%)
collapse Related Readings collapse

Stock Pick From The Pharma Sector

| 11/29/2012 9:00 PM Thursday

Choice Scrip is a Blue Chip stock pick that is expected to give returns within a 6 months-1 year horizon. The recommendation is based on a fundamental analysis of the company.

The company recommended as the Choice Scrip for this issue is a star performer in the pharma sector and an active player in exports.

Here Is Why:

  • It is an outperformer in the domestic pharma market.
  • The company has a strong pipeline of generic drugs.
  • Expected future revenue visibility from its innovative products is USD 800 million (Rs 4400 crore)

The ongoing patent expiry in the US pharma market has been highly beneficial for Indian pharma companies. Many of them have witnessed multifold growth in their topline and bottomline after they started investing in R&D. Mumbai-based Glenmark Pharmaceuticals (GPL) is one such star performer in the sector, which is witnessing strong growth in its business. The strong pipeline of innovative products as well as the focus on low competition niche products are some factors that go in favour of the scrip.

GPL’s business is mainly categorised into two segments, i.e. specialty and generics. Specialty is the main business driver, constituting 58 per cent of its topline, while the remaining 42 per cent comes from the generics segment. In the specialty business, the company manufactures and sells products from high growth therapeutic segments such as respiratory, diabetes, oncology, etc. In the generics segment, it manufactures and sells generics of branded formulations.

Shareholding Pattern As Of September 30, 2012
Promoter and Promoter Group 48.33%
FII 33.12%
DII 6.73%
Public 10.12%
Bodies Corporate 1.70%
Total 100%

Besides its operations in the domestic markets, GPL is also an active player in exports, which form 71 per cent of its total revenues. The company has operations in major regions including USA, Latin America, Japan, Europe, etc., with double-digit growth rates in most of them. Even in the domestic market, the company has outperformed by clocking a growth rate of 19 per cent in FY12 against 16 per cent by the pharma market. The addition of marketing professionals in the domestic market in FY12 has started giving results in the first half of this fiscal, where the company achieved 30 per cent growth in revenues.

The company has a good generic product pipeline assuring strong revenues ahead. In Russia, it has four product approvals in the dermatology segment. In USA, it has 10 approvals for oral contraceptives (OCs) and 19 approvals for derma products. It has monetised some OCs this year, which will rake in revenues going forward. GPL has also entered the Japanese pharma market, from where we expect a consistent revenue stream in the next few years. The company is also making strong footprints in other markets. This will drive its revenues post the US-patent expiries, which are expected to wane from 2015 onwards.

 LAST FIVE QUARTERS (Rs/Cr)
 Sep '12Jun '12Mar '12Dec '11Sep '11
Sales  1255..57 1040.67 1066.2 1031.31 1055.7
Operating Profit 277.9 167.73 224.11 113.4 217.52
Interest  38.38 40.98 35.72 29.06 40.81
Depreciation  32.08 27.48 23.64 23.14 24.72
Taxation  47.71 21.81 7.26 8.42 -23.79
Net Profit/Loss  159.72 80.39 152.23 46.12 55.86
Equity Capital  27.05 27.05 27.05 27.04 27.04

The most compelling factor for the company is its innovative product pipeline. It currently has two products in Phase III clinical trial, progressing towards approval stage. It has another seven products in various stages of clinical trials, which will yield hefty revenues in the future. The company also out-licenses its R&D products, which yield valuable milestone payments every year. Last year, it out-licensed its monoclonal antibody to Sanofi for USD 500 million (Rs 2750 crore). The total revenue visibility from these out-licensed products is USD 800 million (about Rs 4400 crore), which is more than its FY12 annual revenues.

On the financial front, its topline and bottomline have witnessed CAGR of 15 per cent and 24 per cent respectively for the last three-year period. For H1FY13, GPL’s revenues have grown by 27 per cent in the specialty segment and by 50 per cent in generics. The normalised revenues, excluding out- icensed income, grew by 36 per cent to Rs 2295 crore while the net profit grew by 21 per cent to Rs 235 crore.

On the valuations front, the stock is trading at a PE of 25.6x its FY12 earning and 20x its FY13E EPS of Rs 21.70. We expect the scrip to touch a price of Rs 510, giving returns of 17 per cent within one year.

 BEST OF LAST ONE YEAR
Company NameReco. Price (Rs)CMP (Rs)
As of 27-11-2012
Gain (%)
Ajanta Pharma 171.00 364.00 112.87
Strides Arcolab  729.05 1122.00 53.90
GlaxoSmith Kline Consumer Healthcare 2542.00 3685.00 44.96
M&M Financial Services   685.35 993.00 44.89
ING Vysya Bank  325.00 466.00 43.38
Colgate Palmolive (India), 1014.00 1427.00 40.73
Asian Paints  2985.00 4129.00 38.32
Jammu & Kashmir Bank   976.00 1347.00 38.01

 

Find More Articles on: DSIJ Magazine, Choice Scrip, Stock Recommendations, Fundamental Picks, Product, Large Cap

news letter

More for the early bird.

Get the post-market reports and breakfast news right in your inbox. See latest »

DSIJ Mindshare

12345678910Last

Tiger Logistics topline to grow by 10%--buoyant over infra sector status to logistics sector

Tiger Logistics topline to grow by 10%--buoyant over infra sector status to logistics sector

Logistics sector will play a vital role in making the concept of ‘Make in India’ a success. This will be further aided by some of the recent steps taken by Government of India such as granting of infra sector status to logistics sector.

Best and worst Performing Sector Funds of Year 2017

Best and worst Performing Sector Funds of Year 2017

As the year-end has approached most of you are eager to know the mutual fund movers and shakers of the year 2017. Read on to find the performance of various sector dedicated funds.

Markets may start positive, but volatility likely due to F&O expiry

Markets may start positive, but volatility likely due to F&O expiry

The start of the F&O expiry day is likely to be in the green, but volatility may creep in with the progress of the session. The SGX Nifty suggests that the Nifty could open at 10,525 with gains of 32 points at the opening bell. 

Pidilite announces buyback of Rs 500 crore

Pidilite announces buyback of Rs 500 crore

The buyback offer comprises purchase of up to 50,00,000 equity shares. The buyback offer size comprises 0.975 per cent of the total paid-up equity capital of the company.

Bank Nifty drags markets to close in the red

Bank Nifty drags markets to close in the red

The late session fall in Bank Nifty changed the direction of the market, leading to a marginal fall in the benchmark indices. Bank Nifty yet again resisted at its multiple point downward sloping trendline level at 25733.

Six major underperforming MF schemes having higher expense ratios

Six major underperforming MF schemes having higher expense ratios

Mutual funds with a large size of assets under management (AUMs) are supposed to have lower expense ratios. However, there are schemes with large AUMs but having higher expense ratios and generating lower returns. 

Nifty Pharma supports market; Sun Pharma at bullish reversal

Nifty Pharma supports market; Sun Pharma at bullish reversal

Nifty Pharma index has come in as the healer in an otherwise sluggish market. Index has given a consolidation breakout at the 9420 level today and if the it sustains 9420, followed by 9628 on the upside, it has a long way to go.

Ten stocks close to their 52-week low

Ten stocks close to their 52-week low

Following stocks are close to their 52-week low as at 12.35 p.m. on December 27.

Ten stocks close to their 52-week high

Ten stocks close to their 52-week high

The markets on December 27 opened gap down. BSE Sensex is trading at 34,068.15, up by 57.54 points and the Nifty is trading at 10,539.45, up by 7.95 points.

Five stocks with selling interest

Five stocks with selling interest

Overall volumes in futures & options currently stand at 62.75 lakh contracts with a turnover of Rs. 5,19,204.72 crore.